A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2

Journal of Molecular Biology

Volumn 281, Issue 3, 1998, Pages 475-483

  Bera, Tapan K ^a   Onda, Masanori ^a   Brinkmann, Ulrich ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibody engineering; Bivalent dsFv; Cancer therapy

Indexed keywords

IMMUNOGLOBULIN FRAGMENT; IMMUNOTOXIN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PSEUDOMONAS EXOTOXIN;

ANTIBODY AFFINITY; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DISULFIDE BOND; ESCHERICHIA COLI; MOLECULAR STABILITY; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PURIFICATION;

ESCHERICHIA COLI; PSEUDOMONAS; PSEUDOMONAS EXOTOXIN;

EID: 0032555737     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1998.1948     Document Type: Article

References (50)

1. Adams G.P., McCartney J.E., Tai M.S., Oppermann H., Huston J.S., Stafford W.F. III, Bookman M.A., Fand I., Houston L.L., Weiner L.M. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res. 53:1993;4026-4034
2. Adams G.P., McCartney J.E., Wolf E.J., Eisenberg J., Huston J.S., Bookman M.A., Moldofsky P., Stafford W.F. III, Houston L.L., Weiner L.M. Enhanced tumor specificity of 741F8-1 (sFv′)2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation. J. Nucl. Med. 36:1995;2276-2281
3. Bagshawe K.D., Sharma S.K., Springer C.J., Rogers G.T. Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects. Ann. Oncol. 5:1994;879-891
4. Bird R.E., Hardman K.D., Jacobson J.W., Johnson S., Kaufman B.M., Lee S.M., Lee T., Pope S.H., Riordan G.S., Whitlow M. Single-chain antigen-binding proteins. Science. 242:1988;423-426
5. Bjork I., Tanford C. Recovery of native conformation of rabbit immunoglobulin G upon recombination of separately renatured heqavy and light chains at near-neutral pH. Biochemistry. 10:1971;1289-1295
6. Brinkmann U., Pastan I. Immunotoxins against cancer. Biochim. Biophys. Acta. 1198:1994;27-45
7. Brinkmann U., Pastan I. Recombinant immunotoxins from basic research to cancer therapy. Methods. 8:1995;143-156
8. Brinkmann U., Pai L.H., FitzGerald D.J., Willingham M., Pastan I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc. Natl Acad. Sci. USA. 88:1991;8616-8620
9. Brinkmann U., Reiter Y., Jung S.H., Lee B., Pastan I. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc. Natl Acad. Sci. USA. 90:1993;7538-7542
10. Buchner J., Pastan I., Brinkmann U. A method to increase the yield of properly folded recombinant fusion proteins single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal. Biochem. 205:1992;263-270
11. Carson M. Ribbon models of macromolecules. J. Mol. Graph. 5:1987;103-106
12. Chaudhary V.K., Queen C., Junghans R.P., Waldmann T.A., FitzGerald D.J., Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature. 339:1989;394-397
13. Cumber A.J., Ward E.S., Winter G., Parnell G.D., Wawrzynczak E.J. Comparative stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bisFvCys conjugate. J. Immunol. 149:1992;120-126
14. De-Jonge J., Brissinck J., Heirman C., Demanet C., Leo O., Moser M., Thielemans K. Production and characterization of bispecific single-chain antibody fragments. Mol. Immunol. 32:1995;1405-1412
15. Di Fiore P.P., Pierce J.H., Kraus M.H., Segato O., King C.R., Aaronson S.A. erb B-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 237:1989;178-182
16. Freund C., Ross A., Pluckthun A., Holak T.A. Structural and dynamic properties of the Fv fragment and the single-chain Fv fragment of an antibody in solution investigated by heteronuclear three-dimensional NMR spectroscopy. Biochemistry. 33:1994;3296-3303
17. Glockshuber R., Malia M., Pfitzinger I., Pluckthun A. A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry. 29:1990;1362-1367
18. Gruber M., Schodin B.A., Wilson E.R., Kranz D.M. Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J. Immunol. 152:1994;5368-5374
19. Haunschild J., Faro H.-P., Pack P., Pluckthun A. Pharmacokinetic properties of bivalent miniantibodies and comparison to other immunoglobulin forms. Antib. Immunoconj. Radiopharm. 8:1995;111-128
20. Hayden M.S., Linsley P.S., Gayle M.A., Bajorath J., Brady W.A., Norris N.A., Fell H.P., Ledbetter J.A., Gilliland L.K. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system. Therapeut. Immunol. 1:1994;3-15
21. Holliger P., Winter G. Engineering bispecific antibodies. Curr. Opin. Biotechnol. 4:1993;446-449
22. Holliger P., Prospero T., Winter G. "Diabodies" small bivalent and bispecific antibody fragments. Proc. Natl Acad. Sci. USA. 90:1993;6444-6448
23. Holliger P., Brissinck J., Williams R.L., Thielemans K., Winter G. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng. 9:1996;299-305
24. Hudziak R.M., Schlessinger J., Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH/3T3 cells. Proc. Natl Acad. Sci. USA. 84:1987;7159-7163
25. Huston J.S., Levinson D., Mudgett-Hunter M., Tai M.S., Novotny J., Margolies M.N., Ridge R.J., Bruccoleri R.E., Haber E., Crea R., Oppermann H. Protein engineering of antibody binding sites recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl Acad. Sci. USA. 16:1988;5879-5883
26. Huston J.S., Mudgett-Hunter M., Tai M.S., McCartney J., Warren F., Haber E., Oppermann H. Protein engineering of single-chain Fv analogs and fusion proteins. Methods Enzymol. 203:1991;46-88
27. Hwang J., FitzGerald D.J., Adhya S., Pastan I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell. 48:1987;129-136
28. Jungheim L.N., Shepherd T.A. Design of anticancer drugs substrates for antibody targeted enzymes. Chem. Rev. 94:1994;1553-1566
29. King C.R., Kraus M.H., Aaronson S.A. Amplification of a novel v- erb B-related gene in a numan mammary carcinoma. Science. 229:1985;974-976
30. Kreitman R., Pastan I. Accumulation of a recombinant immunotoxin in a tumor in vivo less than 1000 molecules per cell is sufficient for complete responses. Cancer Res. 1998;. In the press
31. Kurucz I., Titus J.A., Jost C.R., Jacobus C.M., Segal D.M. Retargeting of CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria. J. Immunol. 154:1995;4576-4582
32. Mallender W.D., Ferreira S.T., Voss E.J., Coelho S.T. Inter-active-site distance and solution dynamics of a bivalent-bispecific single-chain antibody molecule. Biochemistry. 33:1994;10100-10108
33. McCartney J.E., Tai M.S., Hudziak R.M., Adams G.P., Weiner L.M., Jin D., Stafford W.F. III, Liu S., Bookman M.A., Laminet A.A., Fand I., et al. Engineering disulfide-linked single-chain Fv dimers [(sFv′)2] with improved solution and targeting properties anti-digoxin 26-10 (sFv′)2 and anti-c-erbB-2 741F8 (sFv′)2 made by protein folding and bonded through C-terminal cysteinyl peptides. Protein Eng. 8:1995;301-314
34. Neri D., Momo M., Prospero T., Winter G. High-affinity antigen binding by chelating recombinant antibodies (CRAbs). J. Mol. Biol. 24:1995;367-373
35. Pack P., Kujau M., Schroeckh V., Knupfer U., Wenderoth R., Riesenberg D., Pluckthun A. Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli. Biotechnology. 11:1993;1271-1277
36. Pack P., Muller K., Zahn R., Pluckthun A. Tetravalent miniantibodies with high avidity assembling in Escherichia coli. J. Mol. Biol. 246:1995;28-34
37. Pastan I., Pai L.H., Brinkmann U., FitzGerald D.J. Recombinant toxins new therapeutic agents for cancer. Ann. N. Y. Acad. Sci. 758:1995;345-354
38. Pluckthun A. Mono- and bivalent antibody fragments produced in E. coli. Immunol. Rev. 130:1992;151-188
39. Pluckthun A., Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology. 3:1997;83-105
40. Reiter Y., Brinkmann U., Jung S.-H., Lee B., Kasprzyk P.G., King C.R., Pastan I. Improved binding and anti-tumor activity of a recombinant anti-erbB2 immunotoxin by disulfide-stabilization of the Fv fragment. J. Biol. Chem. 269:1994;18327-18331
41. Reiter Y., Brinkmann U., Jung S.-H., Lee B., Pastan I. Engineering disulfide bonds into conserved framework regions of Fv fragments recombinant immunotoxins containing disulfide-stabilized Fv with improved biochemical characteristics. Protein Eng. 7:1994;697-704
42. Reiter Y., Kreitman R.J., Brinkmann U., Pastan I. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin. Int. J. Cancer. 58:1994;142-149
43. 2 formation in Escherichia coli and for improved in vivo stability. J. Immunol. 151:1993;6954-6961
44. Skerra A., Pluckthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science. 240:1988;1038-1041
45. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Strart S.G., Udove J., Ullrinch A., Press M.F. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712
46. Studier F.W., Moffatt B.A. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J. Mol. Biol. 189:1986;113-130
47. Vasmatzis G., Cornette J., Sezerman U., DeLisi C. TCR recognition of the MHC-peptide dimer structural properties of a ternary complex. J. Mol. Biol. 261:1995;72-89
48. Webber K.O., Reiter Y., Brinkmann U., Kreitman R.J., Pastan I. Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody comparison with its single-chain analog. Mol. Immunol. 4:1995;249-258
49. Yokota J., Yamamoto T., Toyoshima K., Sugimura T., Terada M., Battifora H., Cline M.J. Amplification of c- erb B-2 oncogene in human adenocarcinomas in vivo. Lancet. 2:1986;765-767
50. Yokota T., Milenic D.E., Whitlow M., Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52:1992;3402-3408